文章摘要
郭烽,杨玉兴.替米沙坦对冠心病合并高血压患者过氧化物酶体增殖物激活受体γ表达变化、肝细胞生长因子及肝细胞生长因子受体水平的影响[J].中国临床保健杂志,2020,23(6):804-807.
替米沙坦对冠心病合并高血压患者过氧化物酶体增殖物激活受体γ表达变化、肝细胞生长因子及肝细胞生长因子受体水平的影响
The effect of Telmisartan on the expression of PPAR-γ,HGF and c-met receptor in patients with coronary heart disease complicated with hypertension
投稿时间:2018-05-10  
DOI:10.3969/J.issn.1672-6790.2020.06.020
中文关键词: 冠心病  高血压  PPARγ  肝细胞生长因子  原癌基因蛋白质c-met
英文关键词: Coronary disease  Hypertension  PPAR gamma  Hepatocyte growth factor  Proto-oncogene proteins c-met 〖FL
基金项目:甘肃省卫生厅医药科研计划项目(12925GS2015B1)
作者单位E-mail
郭烽 兰州军区总医院干二科,兰州 730050 chen01yalong@163.com 
杨玉兴 兰州军区总医院干二科,兰州 730050  
摘要点击次数: 257
全文下载次数: 249
中文摘要:
      目的 探讨替米沙坦对冠心病合并高血压患者过氧化物酶体增殖物激活受体γ(PPAR-γ)表达变化、肝细胞生长因子(HGF)及其肝细胞生长因子受体(c-met)水平变化的影响。 方法 选择冠心病合并高血压患者214例,按照随机数表法将患者分为观察组和对照组,各107例。给予两组患者口服阿托伐他汀钙,给予对照组患者口服氨氯地平,给予观察组患者口服替米沙坦。检测并比较两组患者的炎性因子,比较两组患者的超敏C反应蛋白(hs-CRP)水平、PPAR-γ蛋白水平、c-met水平;观察并比较两组患者的血压水平和血脂水平。 结果 两组患者收缩压和舒张压均较治疗前降低(P>0.05);治疗后,两组患者基质金属蛋白酶-9、肿瘤坏死因子-α、白细胞介素6、超敏C反应蛋白等水平均显著降低,观察组显著低于对照组(P<0.05);两组患者PPAR-γ、HGF及c-met水平显著降低,且观察组低于对照组(P<0.05);两组患者均无死亡,观察组患者出现2例不稳定性心绞痛,对照组出现5例不稳定性心绞痛,2例心功能恶化,观察组心血管不良事件发生率高于对照组。 结论 替米沙坦能够显著降低冠心病合并高血压患者PPAR-γ、HGF及其受体水平,改善机体血管内皮功能,对心脏起保护作用,降低心血管不良事件。
英文摘要:
      Objective To investigate the effects of telmisartan on PPAR-gamma expression,HGF and c-met receptor level change in the patients with hypertension and coronary heart disease. Methods 214 cases of patients with coronary artery disease and hypertension patients were selected,all patients were randomly divided into control group and observation group,107 cases in each.Two groups of patients were given atorvastatin oral control group was given oral amlodipine orally,the observation group was given oral telmisartan group,two patients admitted to hospital second days fasting blood 5 mL,extraction of the upper plasma,-80 ℃ refrigerator,determination of MMP-9,IL-6 and HGF levels by enzyme-linked immunosorbent assay,determination of hs-CRP by immune nephelometry.The expression of PPAR-protein was detected by blot gamma Westem cells.After treatment,the two groups were measured blood pressure.The fasting blood glucose,triglyceride,high density lipoprotein cholesterol and low density lipoprotein cholesterol levels were determined.The c-met protein levels in the adjacent tissues were detected by immunohistochemistry.Adverse cardiovascular events were recorded in two groups. Results The systolic pressure and diastolic blood pressure in two groups decreased after treatment (P>0.05).After the treatment,MMP-9,TNF-α,IL-6 and hs-CRP levels were significantly decreased in two groups of patients,and those in observation group were significantly lower than those in control group (P<0.05).PPAR-gamma,HGF and its receptor c-met were significantly decreased in two groups of patients,and those in the observation group were significantly lower than in the control group (P<0.05).No death occurred in two groups,but 2 cases of unstable angina in the observation group,5 cases of unstable angina and 2 cases of deterioration of heart function in the control group occured,and thus the incidence rate of cardiovascular events in observation group was lower than in the control group. Conclusion Telmisartan can significantly reduce PPAR-gamma,HGF and c-met levels in the patients with coronary heart disease and hypertension,improve the vascular endothelial function and reduce the heart cardiovascular adverse events.
查看全文     
关闭
分享按钮